Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update
Key Highlights
- ➤FDA feedback supports refocusing fasedienol Phase 3 on overall social anxiety disorder treatment
- ➤Fasedienol PALISADE-4 extension showed clinically relevant social-anxiety improvement over four months
- ➤Net loss narrowed to $10.7 million from $19.4 million year over year
- ➤Cash, equivalents, and marketable securities totaled $20.0 million at September 30, 2026
- ➤Vistagen expects funding operations into 2027, but not beyond one year
Expert Statements
Shawn Singh, President and Chief Executive Officer of Vistagen
“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder.”
Shawn Singh, President and Chief Executive Officer of Vistagen
“Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update.
“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder,” said Shawn Singh, President and Chief Executive Officer of Vistagen. “Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”
Get started
Create a free account to read the full story.